The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on October 28, Beijing Xiantong International Pharmaceutical Technology Co., Ltd. (Xiantong Pharmaceutical for short) passed the Hong Kong Stock Exchange's main board listing hearing, and GF Securities, CITIC Securities were co-sponsors. According to the Insight Consultation Report, Xiantong Pharmaceutical is the first company in China to (i) obtain marketing approval for innovative radiopharmaceuticals; (ii) an enterprise that obtained a license to manufacture innovative radiopharmaceuticals under the MAH status; and (iii) completed clinical trials registered for therapeutic radioligands and received an NDA from the State Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.